Drug · DIN 02487152
LIBTAYO
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since December 8, 2023; first marketed May 24, 2019.
- Drug Identification Number (DIN)
- 02487152
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Cemiplimab L01FF06
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CEMIPLIMAB | 250 MG | 5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 10, 2019: NOC 22053New Drug Submission (NDS)
Other DINs named LIBTAYO
- DIN 02487144 · Marketed